OBJECTIVE: Human endothelial cells use the multidrug resistance protein-1 (MRP1) to export glutathione disulfide (GSSG). This can promotes thiol loss during states of increased glutathione oxidation. We investigated how MRP1 modulates blood pressure and vascular function during angiotensin II-induced hypertension. METHODS AND RESULTS: Angiotensin II-induced hypertension altered vascular glutathione flux by increasing GSSG export and decreasing vascular levels of glutathione in wild-type (FVB) but not in MRP1-/- mice. Aortic endothelium-dependent vasodilatation was reduced in FVB after angiotensin II infusion, but unchanged in MRP1-/- mice. Aortic superoxide (O2*-) production and expression of several NADPH oxidase subunits were increased by angiotensin II in FVB. These effects were markedly blunted in MRP1-/- vessels. The increase in O2*- production in FVB vessels caused by angiotensin II was largely inhibited by L-NAME, suggesting eNOS uncoupling. Accordingly, aortic tetrahydrobiopterin and levels of NO were decreased by angiotensin II in FVB but were unchanged in MRP1-/-. Finally, the hypertension caused by angiotensin II was markedly blunted in MRP1-/- mice (137+/-4 versus 158+/-6 mm Hg). CONCLUSION: MRP1 plays a crucial role in the genesis of multiple vascular abnormalities that accompany hypertension and its presence is essential for the hypertensive response to angiotensin II.
OBJECTIVE:Human endothelial cells use the multidrug resistance protein-1 (MRP1) to export glutathione disulfide (GSSG). This can promotes thiol loss during states of increased glutathione oxidation. We investigated how MRP1 modulates blood pressure and vascular function during angiotensin II-induced hypertension. METHODS AND RESULTS: Angiotensin II-induced hypertension altered vascular glutathione flux by increasing GSSG export and decreasing vascular levels of glutathione in wild-type (FVB) but not in MRP1-/- mice. Aortic endothelium-dependent vasodilatation was reduced in FVB after angiotensin II infusion, but unchanged in MRP1-/- mice. Aortic superoxide (O2*-) production and expression of several NADPH oxidase subunits were increased by angiotensin II in FVB. These effects were markedly blunted in MRP1-/- vessels. The increase in O2*- production in FVB vessels caused by angiotensin II was largely inhibited by L-NAME, suggesting eNOS uncoupling. Accordingly, aortic tetrahydrobiopterin and levels of NO were decreased by angiotensin II in FVB but were unchanged in MRP1-/-. Finally, the hypertension caused by angiotensin II was markedly blunted in MRP1-/- mice (137+/-4 versus 158+/-6 mm Hg). CONCLUSION:MRP1 plays a crucial role in the genesis of multiple vascular abnormalities that accompany hypertension and its presence is essential for the hypertensive response to angiotensin II.
Authors: Anna E Dikalova; Alfiya T Bikineyeva; Klaudia Budzyn; Rafal R Nazarewicz; Louise McCann; William Lewis; David G Harrison; Sergey I Dikalov Journal: Circ Res Date: 2010-05-06 Impact factor: 17.367
Authors: David Pimentel; Dagmar Johanna Haeussler; Reiko Matsui; Joseph Robert Burgoyne; Richard Alan Cohen; Markus Michael Bachschmid Journal: Antioxid Redox Signal Date: 2012-03-15 Impact factor: 8.401
Authors: Sergey I Dikalov; Rafal R Nazarewicz; Alfiya Bikineyeva; Lula Hilenski; Bernard Lassègue; Kathy K Griendling; David G Harrison; Anna E Dikalova Journal: Antioxid Redox Signal Date: 2013-10-30 Impact factor: 8.401
Authors: Nyssa E Hoch; Tomasz J Guzik; Wei Chen; Tenecia Deans; Samer A Maalouf; Petra Gratze; Cornelia Weyand; David G Harrison Journal: Am J Physiol Regul Integr Comp Physiol Date: 2008-12-10 Impact factor: 3.619
Authors: Sergey Dikalov; Hana Itani; Bradley Richmond; Aurelia Vergeade; S M Jamshedur Rahman; Olivier Boutaud; Timothy Blackwell; Pierre P Massion; David G Harrison; Anna Dikalova Journal: Am J Physiol Heart Circ Physiol Date: 2019-01-04 Impact factor: 4.733
Authors: Vladimir V Shuvaev; Melpo Christofidou-Solomidou; Faiz Bhora; Karine Laude; Hua Cai; Sergei Dikalov; Evguenia Arguiri; Charalambos C Solomides; Steven M Albelda; David G Harrison; Vladimir R Muzykantov Journal: J Pharmacol Exp Ther Date: 2009-08-19 Impact factor: 4.030